MX352861B - Compuestos para tratar la atrofia muscular espinal. - Google Patents

Compuestos para tratar la atrofia muscular espinal.

Info

Publication number
MX352861B
MX352861B MX2014007877A MX2014007877A MX352861B MX 352861 B MX352861 B MX 352861B MX 2014007877 A MX2014007877 A MX 2014007877A MX 2014007877 A MX2014007877 A MX 2014007877A MX 352861 B MX352861 B MX 352861B
Authority
MX
Mexico
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
smn1
Prior art date
Application number
MX2014007877A
Other languages
English (en)
Other versions
MX2014007877A (es
Inventor
Pinard Emmanuel
G Woll Matthew
Chen Guangming
Choi Soongyu
Dakka Amal
Huang Song
Mitchell Karp Gary
Lee Chang-Sun
Li Chunshi
Narasimhan Jana
Naryshkin Nikolai
Paushkin Sergey
Qi Hongyan
A Turpoff Anthony
L Weetall Marla
Welch Ellen
Yang Tianle
Zhang Nanjing
Zhang Xiaoyan
Zhao Xin
Ratni Hasane
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2014007877A publication Critical patent/MX2014007877A/es
Publication of MX352861B publication Critical patent/MX352861B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones de los mismos y usos con los mismos para tratar la atrofia muscular espinal. En una modalidad específica, se proporcionan en la presente compuestos de una forma que pueden utilizarse para modular la inclusión del exón 7 de SMN2 en el ARNm que se transcribe a partir del gen SMN2. En otra modalidad específica, se proporcionan en la presente compuestos de una forma que puede utilizarse para modular la inclusión del exón 7 de SMN1 en ARNm que se transcribe a partir del gen SMN1. Aún en otra modalidad, se proporcionan en la presente compuestos de una forma que puede utilizarse para modular la inclusión del exón 7 de SMN1 y SMN2 en ARNm que se transcribe a partir de los genes SMN1 y SMN2, respectivamente.
MX2014007877A 2011-12-30 2012-12-28 Compuestos para tratar la atrofia muscular espinal. MX352861B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161582064P 2011-12-30 2011-12-30
PCT/US2012/071899 WO2013101974A1 (en) 2011-12-30 2012-12-28 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2014007877A MX2014007877A (es) 2015-01-16
MX352861B true MX352861B (es) 2017-12-13

Family

ID=48698624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007877A MX352861B (es) 2011-12-30 2012-12-28 Compuestos para tratar la atrofia muscular espinal.

Country Status (11)

Country Link
US (2) US9617268B2 (es)
EP (1) EP2797592B1 (es)
JP (1) JP6193881B2 (es)
KR (1) KR102057351B1 (es)
CN (1) CN104244944B (es)
BR (1) BR112014016287B1 (es)
CA (1) CA2861609C (es)
EA (1) EA029984B1 (es)
HK (1) HK1202059A1 (es)
MX (1) MX352861B (es)
WO (1) WO2013101974A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809322B9 (en) 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
SG10201609188WA (en) 2012-02-10 2016-12-29 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9914722B2 (en) 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014102778A2 (en) * 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
CN103360269B (zh) * 2013-07-16 2015-07-08 临海市联盛化学有限公司 一种3-氯-2-氨基苯酚的制备方法
CA2915764A1 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
WO2015095449A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
AU2015250994B2 (en) 2014-04-22 2018-12-20 Torqur Ag Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
PT3143025T (pt) 2014-05-15 2019-12-03 Hoffmann La Roche Compostos para tratamento da atrofia muscular espinhal
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
MX2016015248A (es) * 2014-06-25 2017-02-23 Hoffmann La Roche Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
EP3377476B1 (en) * 2015-11-16 2022-10-26 PTC Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
PL3386511T3 (pl) 2015-12-10 2021-11-08 Ptc Therapeutics, Inc. Sposoby leczenia choroby huntingtona
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
AU2017223706A1 (en) * 2016-02-23 2018-09-20 Indiana University Research & Technology Corporation Combination therapies for treatment of spinal muscular atrophy
CN108779115B (zh) 2016-10-14 2021-02-26 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
WO2018098446A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Methods for modulating rna splicing
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
EP3684766A1 (en) * 2017-09-22 2020-07-29 H. Hoffnabb-La Roche Ag Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
KR20210025625A (ko) 2018-06-27 2021-03-09 리보르나 바이오사이언시스, 아이엔씨. 척수성 근위축증 예방제 또는 치료제
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020146449A1 (en) * 2019-01-08 2020-07-16 Texas Tech University System Small molecule analogs of the protein e4orf1 in the treatment and prevention of metabolic disorders
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
CA3103900A1 (en) * 2019-03-01 2020-09-10 Illumina Cambridge Limited Exocyclic amine substituted coumarin compounds and their uses as fluorescent labels
CN109943092A (zh) * 2019-04-09 2019-06-28 浙江工业大学 具有高荧光量子产率的咪唑类香豆素类染料及其合成方法
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
CN114315807B (zh) * 2022-01-05 2023-09-15 江南大学 一种吡啶鎓盐光引发剂及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020636B (de) * 1954-11-12 1957-12-12 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen
FR1320597A (fr) * 1961-04-27 1963-03-08 Geigy Ag J R Nouvelles 3-phényl-7-pyrazolyl-coumarines, utilisables en particulier comme azurants optiques
NL121271C (es) 1961-04-27
US3311636A (en) * 1963-03-14 1967-03-28 Upjohn Co Organic chemical compounds and process
DE1245306B (de) * 1963-05-11 1967-07-27 Bayer Ag Aufhellungsmittel
DE1594845C3 (de) * 1966-03-19 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte v-Triazol-(2)-yl-cumarinverbindungen und deren Verwendung als Aufhellungsmittel
CH505089A (de) * 1968-08-23 1971-03-31 Bayer Ag Verfahren zur Herstellung von 3-substituierten-7-Aminocumarinen
JPS5023687B2 (es) * 1972-03-07 1975-08-09
CH620322B (de) * 1976-03-26 Ciba Geigy Ag Verwendung von 3-phenyl-7-(v-triazol-2-yl)-cumarinen zum optischen aufhellen von organischen materialien.
FR2361680A1 (fr) * 1976-08-11 1978-03-10 Du Pont Plaques d'impression planographiques et leur preparation
DE2807761A1 (de) 1978-02-23 1979-08-30 Basf Ag Cumarinderivate
DE2815956A1 (de) * 1978-04-13 1979-10-18 Bayer Ag Verfahren zur herstellung von in 2-stellung substituierten triazolen-1,2,3
DE2950291A1 (de) * 1979-12-14 1981-06-19 Basf Ag, 6700 Ludwigshafen Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen
JPS56140990A (en) * 1980-04-07 1981-11-04 Showa Kagaku Kogyo Kk 3-phenylcoumarin derivative bearing dicarbonylimide group
DE3101141A1 (de) 1981-01-16 1982-09-02 Bayer Ag, 5090 Leverkusen Triazolylcumarinverbindungen, sowie deren herstellung und verwendung als optiche aufheller, scintillatoren und laserfarbstoffe
JPS62267285A (ja) 1986-05-16 1987-11-19 Kyorin Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
ATE106566T1 (de) 1989-11-21 1994-06-15 Bayer Ag Optischer biosensor.
EP0448241A3 (en) * 1990-02-28 1992-03-04 Konica Corporation Light-sensitive silver halide photographic material
CA2123740C (en) * 1993-05-19 2002-12-17 Hee-Gwon Chae Electric vacuum cleaner
JPH073179A (ja) * 1993-06-15 1995-01-06 Nippon Kayaku Co Ltd インクジェットプリント用インク組成物及びこれを用いる染色法
KR20040068240A (ko) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
CN1180016C (zh) * 2002-04-04 2004-12-15 中国石化上海石油化工股份有限公司 用于制造增白聚丙烯纤维的增白聚丙烯母粒
US7176227B2 (en) * 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
WO2006078834A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) * 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
EP2121678B1 (en) * 2006-12-20 2010-11-03 NeuroSearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2011511031A (ja) * 2008-02-05 2011-04-07 ノイロサーチ アクティーゼルスカブ 新規な９−アザ−ビシクロ［３．３．１］ノン−３−イルオキシクロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
DE102008018132A1 (de) * 2008-04-09 2009-10-15 Henkel Ag & Co. Kgaa Kationische Direktzieher und Mittel zum Färben von keratinhaltigen Fasern
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR101646804B1 (ko) 2008-10-29 2016-08-08 메르크 파텐트 게엠베하 액정 디스플레이
EP2809322B9 (en) 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
SG10201609188WA (en) 2012-02-10 2016-12-29 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9914722B2 (en) 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy

Also Published As

Publication number Publication date
JP6193881B2 (ja) 2017-09-06
BR112014016287A2 (pt) 2017-07-04
JP2015504057A (ja) 2015-02-05
HK1202059A1 (en) 2015-09-18
KR102057351B1 (ko) 2019-12-18
MX2014007877A (es) 2015-01-16
EA201491296A1 (ru) 2015-01-30
CA2861609C (en) 2021-02-16
EP2797592A4 (en) 2016-01-13
US20150119380A1 (en) 2015-04-30
CA2861609A1 (en) 2013-07-04
CN104244944A (zh) 2014-12-24
WO2013101974A8 (en) 2019-03-07
CN104244944B (zh) 2018-06-08
EP2797592B1 (en) 2019-08-28
BR112014016287B1 (pt) 2022-08-09
KR20140128310A (ko) 2014-11-05
USRE47689E1 (en) 2019-11-05
EA029984B1 (ru) 2018-06-29
WO2013101974A1 (en) 2013-07-04
EP2797592A1 (en) 2014-11-05
US9617268B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
MX352861B (es) Compuestos para tratar la atrofia muscular espinal.
EP3495485A3 (en) Exon skipping compositions for treating muscular dystrophy
MX2019008209A (es) Composiciones para el salto del exon para el tratamiento de distrofia muscular.
MX2019008164A (es) Composiciones mejoradas para el salto de exones para tratar distrofia muscular.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
BR112014018027A8 (pt) Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn
MX336381B (es) Boronatos como inhibidores de arginasa.
PH12014501964A1 (en) Cyclic amides as metap-2 inhibitors
MY172457A (en) Composition and methods for highly efficient gene transfer using aav capsid variants
MX2015013117A (es) Composiciones mejoradas para tratar distrofia muscular.
GB0920703D0 (en) Compositions containing satiogens and methods of use
MY162933A (en) Chemical compounds
MX2013008212A (es) Derivados de 7-azaindol.
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
TW201712120A (en) Multiple exon skipping compositions for DMD
NZ704741A (en) Neprilysin inhibitors
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY163202A (en) Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
MY156963A (en) Ethanol compositions
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors

Legal Events

Date Code Title Description
FG Grant or registration